<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30036740</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-0852</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>101</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>European journal of cancer (Oxford, England : 1990)</Title>                <ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.</ArticleTitle>            <Pagination>                <MedlinePgn>87-94</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0959-8049(18)30942-0</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2018.06.028</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Risk factors for breast cancer relapse are well-known, such as large tumour size or lymph node involvement. The aim of our study was to analyse the influence of bone mineral density, fractures and bisphosphonate or vitamin D prescription on 10 years' breast cancer outcome.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This is a longitudinal and prospective cohort of 450 postmenopausal women with local oestrogen receptor (ER)+ breast cancer. For every patient, we analysed tumour characteristics, bone status at the beginning of aromatase inhibitor treatment and 10 years' cancer outcome with Cox model.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean follow-up was 10.3 ± 3.0 years. Seventy nine women died, and 75 had a relapse; 30.7% had a history of fracture, 16.9% had a T-score ≤ -2.5 and 11.3% had vitamin D deficiency. Bisphosphonates were prescribed to 35.3% women for osteoporosis for a mean duration of 5 ± 1.7 years. Tumour size (hazard ratio [HR] = 1.32, P ≤ 0.01) and the number of lymph nodes involved (HR = 1.07, P = 0.03) were significantly associated with relapse. Bisphosphonate treatment was significantly associated with a decreased risk of relapse (HR = 0.51, P = 0.03). Age at cancer diagnosis (HR = 1.07, P ≤ 0.01) and vitamin D deficiency (HR = 1.85, P = 0.04) were significantly associated with an increased risk of death, whereas bisphosphonate treatment was associated with a decreased risk of death (HR = 0.46, P = 0.01).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Osteoporosis treatment, including vitamin D and bisphosphonates, is associated with a 50% reduction of relapse and death in women treated with aromatase inhibitors for ER+ breast cancer.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Bouvard</LastName>                    <ForeName>B</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Rheumatology, University Hospital, Angers, France; Research Group on Bone Remodeling and BioMaterials UPRES EA 4658, University Hospital, Angers, France. Electronic address: bebouvard@chu-angers.fr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chatelais</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Rheumatology, University Hospital, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Soulié</LastName>                    <ForeName>P</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Oncology, Integrated Centre of Oncology, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hoppé</LastName>                    <ForeName>E</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Rheumatology, University Hospital, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Saulnier</LastName>                    <ForeName>P</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Biostatistics and Methodology Unit, University Hospital, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Capitain</LastName>                    <ForeName>O</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Oncology, Integrated Centre of Oncology, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mege</LastName>                    <ForeName>M</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Radiotherapy, Integrated Centre of Oncology, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mesgouez-Nebout</LastName>                    <ForeName>N</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Radiotherapy, Integrated Centre of Oncology, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jadaud</LastName>                    <ForeName>E</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Radiotherapy, Integrated Centre of Oncology, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abadie-Lacourtoisie</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Oncology, Integrated Centre of Oncology, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Campone</LastName>                    <ForeName>M</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Oncology, Integrated Centre of Oncology, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Legrand</LastName>                    <ForeName>E</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Rheumatology, University Hospital, Angers, France; Research Group on Bone Remodeling and BioMaterials UPRES EA 4658, University Hospital, Angers, France.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>20</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Eur J Cancer</MedlineTA>            <NlmUniqueID>9005373</NlmUniqueID>            <ISSNLinking>0959-8049</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Bisphosphonates</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Osteoporosis</Keyword>            <Keyword MajorTopicYN="N">Vitamin D</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30036740</ArticleId>            <ArticleId IdType="pii">S0959-8049(18)30942-0</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejca.2018.06.028</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>